Moody Aldrich Partners’s Apogee Therapeutics APGE Stock Holding History

Moody Aldrich Partners’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-29,080	Closed	-$2.45M	–	184
2026 Q1	$2.45M	Buy	29,080 +11,916	+69%	+$865K	0.44%	98
2025 Q4	$1.3M	Sell	17,164 -848	-5%	-$53.4K	0.24%	115
2025 Q3	$716K	Sell	18,012 -3,620	-17%	-$138K	0.14%	117
2025 Q2	$939K	Buy	+21,632	New	+$823K	0.18%	112

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Moody Aldrich Partners's APGE Position: Q2 2026 in Review

Moody Aldrich Partners sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 29,080 shares — an estimated $2.45M sold.

Moody Aldrich Partners first reported a position in APGE in Q2 2025 and held it in 4 quarters. The position peaked at $2.45M in Q1 2026. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Moody Aldrich Partners reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
Moody Aldrich Partners sold 29,080 Apogee Therapeutics shares in Q2 2026, an estimated $2.45M.
Moody Aldrich Partners first reported a position in Apogee Therapeutics in Q2 2025 and held it in 4 quarters.
Moody Aldrich Partners's Apogee Therapeutics position peaked at $2.45M in Q1 2026.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.